Clearside Biomedical

Clearside Biomedical Gross Margin

Delisted

The Gross Margin of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 91.05 %. In the previous year, Gross Margin was 95.68 % — a change of -4.85% (lower).

Gross Margin

91.05 %

YoY

-4.85%

Last updated:

Gross Margin of Clearside Biomedical is 2024 91.05 % . Gross Margin of Clearside Biomedical was 2023 95.68 % . It decreases by -4.85% lower compared to the previous year.

For Clearside Biomedical, the gross margin of 91.0% is up versus 84.2% a few years ago.

The Clearside Biomedical Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
84.21 USD
Jan 1, 2023
95.68 USD
Jan 1, 2024
91.05 USD
The Clearside Biomedical Gross Margin history
YEARGross MarginYoY
91.05 %-4.85%
95.68 %+13.63%
84.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Gross Margin of Clearside Biomedical is 91.05 % in 2024.

Gross Margin of Clearside Biomedical changed from 95.68 % to 91.05 %, representing a -4.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Clearside Biomedical

All Key Metrics — Clearside Biomedical